41085-53-4

Upstream product

• 3112-85-4 methylphenylsulfonate 
• 6276-04-6 3,5-dinitroiodobenzene 
• 20277-69-4 sodium methansulfinate 
• 618-87-1 3, 5-dinitroaniline 
• 64673-55-8 3,5-dinitrophenyl thiocyanate 
• 41085-57-8 Methyl-<3,5-dinitro-phenyl>-sulfid 

Downstream Products

• 945397-19-3 5-methylsulfonylbenzene-1,3-diamine 
• 1335496-68-8 C₉H₁₂N₂O₄S 
• 1335140-53-8 [3-[(difluoromethyl)oxy]-5-(methylsulfonyl)phenyl]amine 
• 1335140-52-7 1-[(difluoromethyl)oxy]-3-(methylsulfonyl)-5-nitrobenzene 
• 1335140-51-6 3-(methylsulfonyl)-5-nitrophenol 
• 62606-16-0 1-iodo-3-(methylsulfonyl)-5-nitrobenzene 
• 62606-14-8 1-chloro-3-(methylsulfonyl)-5-nitrobenzene 
• 62606-02-4 3-methoxy-5-(methylsulfonyl)aniline 
• 62606-01-3 3-iodo-5-(methylsulfonyl)aniline 
• 62605-99-6 3-chloro-5-(methylsulfonyl)aniline 
• 62606-17-1 1-(methyloxy)-3-(methylsulfonyl)-5-nitrobenzene 

Relevant academic research and scientific papers

INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS

Disclosed are compounds having the formula: or a salt thereof, wherein A, n, R1, R1A, and R2 are as defined herein, and methods of making and using the same.

PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS

Disclosed are compounds having the formula (I): wherein Z, n, R1, R1A, R3, R4, and R5 are as defined herein, and methods of making and using the same.

PYRIMIDINE DERIVATIVES

The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, ring A, n, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.

Inhibitors of the tyrosine kinase EphB4. Part 2: Structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines

Crystallographic studies of a range of 3-substituted anilinopyrimidine inhibitors of EphB4 have highlighted two alternative C-2 aniline conformations and this discovery has been exploited in the design of a highly potent series of 3,5-disubstituted anilin

Pteridinone derivatives as PI3-kinases inhibitors

New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.